Major, RW
Davies, MJ
Crasto, W
Gray, LJ
Webb, DR
Khunti, K
Article History
Received: 9 January 2014
Revised: 9 May 2014
Accepted: 11 June 2014
First Online: 14 August 2014
Competing interests
: Davies MJ—has acted as a consultant, advisory board member and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme and Roche, and as a speaker for Servier. She has received grants in support of investigator and investigator initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Merck Sharp & Dohme, GlaxoSmithKline and Servier. Webb DR—Novo Nordisk Research Foundation. Khunti K—has acted as a consultant and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme. He has received grants in support of investigator and investigator initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Boehringer Ingelheim and Merck Sharp & Dohme. The rest of the authors declare no conflict of interest.